QuidelOrtho to Participate in 44th Annual William Blair Growth Stock Conference
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced that members of its management team are scheduled to participate in the 44th Annual William Blair Growth Stock Conference on June 5, 2024, in Chicago, IL.
The Company will host a presentation at 1:20 p.m. CT. Interested parties can access the live webcast and replay in the “Events Presentations” section of the “Investor Relations” page of QuidelOrtho’s website at https://ir.quidelortho.com/.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.
Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.
Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects and a more informed path is illuminated for each of us.
QuidelOrtho is advancing diagnostics to power a healthier future.
For more information, please visit www.quidelortho.com.
Source: QuidelOrtho Corporation
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523812581/en/
QuidelOrtho Corp. Aktie
Die QuidelOrtho Corp. Aktie wird von der Community mit mehreren Buy-Einschätzungen unterstützt.
Mit einem Kursziel von 59 € für QuidelOrtho Corp. könnte der aktuelle Kurs von 41.0 € um mehr als 20% steigen.